Table 1.
Patients demographic and clinical profiles
| Variables | Control group (n = 149) | Parecoxib group (n = 147) |
|---|---|---|
| Gender ratio (male/female) | 73/76 | 71/76 |
| Age (years) | 43.2 ± 14.3 | 44.7 ± 13.8 |
| Height (cm) | 158.6 ± 7.1 | 159.1 ± 7.4 |
| Weight (kg) | 57.9 ± 2.4 | 57.6 ± 2.3 |
| BMI (kg m−2) | 23.2 ± 3.9 | 23.3 ± 3.9 |
| EF (%) | 62.2 ± 6.9 | 61.2 ± 7.4 |
| Cardiac function (NYHA) | ||
| II (n) | 91 | 92 |
| III (n) | 58 | 55 |
| Diabetes (n) | 4 | 5 |
| Hypertension (n) | 10 | 7 |
| Smoker (n) | 18 | 20 |
| Prosthesis (n) | ||
| Bioprosthesis | 5 | 4 |
| Mechanical prosthesis | 144 | 143 |
| Pre‐operative platelet counts (103 μl−1) | 230.7 ± 68.5 | 228.0 ± 59.3 |
| Pre‐operative total leucocyte counts (103 μl−1) | 6.3 ± 1.0 | 6.3 ± 0.8 |
Data are presented as mean ± SD and as absolute numbers, respectively. BMI, body mass index; EF, ejection fraction; NYHA, New York Heart Association.